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Summary
Intramuscular (i.m.) injections of promethazine in 25 mg
or 50 mg dosages are commonly used to treat space
motion sickness in astronauts. The present study
examined the effects of i.m. injections of promethazine
on neuropsychological performance, mood states, and
motion sickness tolerance in humans. Twelve men, mean
age 36 _+3.1, participated in one training (no injections)
and three treatment conditions: a 25 mg injection of
promethazine, a 50 mg injection of promethazine, and a
placebo injection of sterile saline. Each condition, spaced
at 7 day intervals, required an 8-10 hr session in which
subjects were given four repetitions of 12 performance
tasks, and one rotating chair motion sickness test. On
the training day subjects were trained on each task to
establish stability and proficiency. On treatment days,
the order in which the drug or placebo was assigned to
subjects was counterbalanced and a double-blind tech-
nique was used. Statistically significant decrements in
performance were observed on 10 of 12 tasks when
subjects were given 25 mg or 50 mg of promethazine as
compared to the placebo. Performance decrements were
associated with mean blood alcohol dose equivalency
levels of 0.085% for 25 mg and 0.137% for 50 mg
dosages. The mood scale results showed significant
changes in individual subjective experiences with
maximum deterioration in the arousal state and fatigue
level. When compared to placebo significant increases in
motion sickness tolerance were found for both dosages of
promethazine. These data suggest that effective dosages
of promethazine currently used to counteract motion
sickness in astronauts may significantly impair task
components of their operational performance.
Introduction
The consequences of spaceflight are both physiological
and psychological and may lead to operationally
significant medical and behavioral problems. In recent
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years, the drug promethazine has been administered to
crew members early in the space mission as a prophy-
lactic treatment for space motion sickness. Concern that
anti-motion sickness medications cause side effects that
impair operational performance has provided impetus to
study drug effects on both human physiology and
performance.
Observations that intramuscular (i.m.) injections of
promethazine are effective in attenuating motion sickness
have been evaluated during both _ound-based and space
studies. I.m. injections of promethazine were first used
during a shuttle flight in March 1989 and have been used
on 14 other occasions since (ref. 1). Promethazine and its
efficacy in the treatment of space motion sickness were
evaluated using standardized questions administered
during post flight debriefings. Results showed that 25%
of crewmembers treated with i.m. injections of prometha-
zine were "sick" on flight day 2, compared to 50% of
crew members who did not receive promethazine (ref. 1).
The efficacy of i.m. injections of promethazine as a
countermeasure for motion sickness was also evaluated
on subjects who experienced symptoms during parabolic
flight. Within 10 min of 50 mg i.m. injection of prometha-
zine, 78% of individuals experienced symptom relief,
whereas 25 mg of promethazine was not effective (ref. 2).
I.m. injections (25 mg) of promethazine increased motion
sickness tolerance by 78% during exposure to cross-
coupled angular accelerations (ref. 3). In the latter study,
i.m. injections were administered 30 min before a rotating
chair test, and the criterion for improvements was the
number of head movements subjects could tolerate as
compared to the number of head movements when they
received a placebo.
The Physician's Desk Reference (1995, p. 2711 ) cautions
under Information for Patients that "... Phenergran
(promethazine) may cause marked drowsiness or impair
the mental and/or physical abilities required for the
performance of potentially hazardous tasks such as
driving a vehicle or operating machinery." Ground-based
studies have shown that significant decrements in per-
formance scores, psychomotor function, information
processing, and alertness may occur with both oral and
i.m.injectionsofpromethazine.Foranoraldoseof
promethazine(12.5mgand25mg),maximaleffectsmay
beseenoninformationprocessingandpsychomotor
performancetestedat2hrintervals,within3-4hrafter
ingestion,withareturntobaselineafter8-9hr(ref.4).
Inanotherstudy,impairedynamictrackingperformance
andreducedabilitytomaintainvisualfixationwere
observedfollowingoralingestionof25mgof
promethazine(r f.5).
Theassessmentofperformanceinspaceonsmallsamples
ofsubjectsnecessitatestheuseofwithin-subjects,
repeated-measuresdesigns.Thetimerestrictionsalso
requiretheuseofperformancemeasuresthatdemonstrate
rapidstabilityandreproducibilityforbrieftestingperiods.
TheAutomatedPerformanceT stSystem(APTS)isan
assessmenttoolforhumanperformanceandcognition
(ref.6).TheAPTSwasdevelopedwithemphasison
within-subjects,repeated-measuresdesigns,andhasbeen
provenbothreliableandvalidinanumberofinvestiga-
tions;administrationftheAPTStakesapproximately
15min(refs.7-11).
Jeanneret(ref.12)reportedthatahighpercentageof
attributesassociatedwithsuccessfuljobperformancein
variousNASAmissionspecialisttasksaremeasuredby
theAPTS.Sixkeycognitiveabilitieswereidentifiedby
thisstudythatarerequiredofindividualsperforming
anyofthe14missionspecialtyfunctions.These are:
(1) intelligence; (2) verbal comprehension; (3) numerical
computation; (4) arithmetic reasoning; (5) convergent
thinking; and (6) short term memory. Three perceptual
aptitudes were found to be the most essential require-
ments across mission specialty functions: (1)spatial
visualization; (2) visual form perception; and (3) per-
ceptual speed. There were two psychomotor abilities
found to be especially important job requirements:
(1) eye-hand coordination and (2) simple reaction time.
The APTS has been used extensively to study the effects
of environmental and chemical stressors on human
performance. These include hypobaric hypoxia (ref. 13),
30 days of bed rest (ref. 14), head-down tilt (ref. 15),
scopolamine and amphetamine (ref. 10), promethazine,
blood alcohol content (ref. 13), sleep deprivation (ref. 16),
and a variety of other conditions (ref. 17). In addition,
performance on APTS tests are predictive of perfor-
mances in a flight simulator, and on tank gunnery
simulators (ref. 18). The results of all of these studies are
concordant in that the APTS is a sensitive metric for
detecting changes in performance.
Jeanneret (ref. 12) demonstrated that one psychomotor
skill which was most important to the job requirements of
astronauts was "eye-hand coordination." This skill is
reliably tested by pursuit tracking tasks, i.e., vigilant
observation of a moving visual target with coordinated
hand-movements. During typical tracking tasks, the
subject is required to maintain contact with the target
using a hand-held stylus, hence directly testing "eye-hand
coordination." The APTS version used in this study
contained the Air Combat Maneuver (ACM) tracking
task. However, in an early study by Kennedy (ref. 13), it
was shown that mean performance on this task failed to
stabilize on I0 trials.
Because the ACM task was not reliable, a critical tracking
task (CTT) was used in the present study. The CTT was
developed as a simple method of evaluating a subject's
eye-hand-coordination or manual control ability (ref. 19).
It has been used extensively as a means of evaluating the
effects of alcohol and/or drugs on a person's skill in
performing a manual task (refs. 20 and 21). Since the
1950s the CTT has been used by the U.S. Air Force to
investigate pilot's abilities to perform inflight (refs. 22
and 23). NASA has used this test to assess the impact of
environmental stressors (e.g., isolation and noise-levels)
on an astronaut's ability to carry out mission duties
(ref. 24) and the U.S. Navy has used it to study the effects
of rough water operations on crew performance (ref. 25).
Lastly, a mood and sleep quality scale (ref. 14) was
included in this study as a means of assessing some of the
side effects of promethazine on mood state changes in
arousal, fatigue, concentration, psychological tension,
and physical discomfort. This scale provides fast and
reliable mood assessment (ref. 26), with a high degree
of mood state resolution and less chance of subject
non-compliance, response stereotyping or remembered
responses (ref. 27). The test included eight mood scales,
two sleep questions extracted from the St. Mary's sleep
questionnaire (ref. 28) to document sleep latency and
disturbance, and a self-rated estimate of overall change in
performance proficiency between tests.
The general aim of the present study was to examine the
effects of promethazine on motion sickness tolerance,
performance and subjective mood states. The specific
objectives were: (1) to determine if promethazine, given
in both 25 and 50 mg fixed dosages, increases motion
sickness tolerance; (2) to determine if performance
decrements are greater with the higher dosage of pro-
methazine; and (3) to determine if performance decre-
ments found during both drug treatment conditions are
associated with specific changes in mood states (e.g.,
decreased arousal or motivation).
Methods
Subjects
Twelve men, mean age 36 -+3.1 (ranging between 30 and
40 years old), weighing between 68 and 82 kg, and who
were right-handed, participated in this study. All subjects
were certified to be in good physical health by a medical
examination, and had no history of cardio-pulmonary
disease nor requirement for chronic medication. As part
of the medical examination, all subjects were screened for
HIV. Their voluntary participation was solicited after all
procedures and risks associated with experiment had
been explained to them, and they were informed of the
requirement that they refrain from using medications
(e.g., antihistamines for colds or allergies) during the
course of the study. The research was reviewed and
approved by the NASA Ames Research Center Human
Research Evaluation Review Board.
Experimental Protocol
Each subject participated in one training condition
(no injection) and three treatment conditions: a 25 mg
i.m. injection of promethazine, a 50 mg i.m. injection of
promethazine, and a placebo i.m. injection of sterile
saline. Each condition, spaced at 7 day intervals, required
an 8-10 hr session in which subjects were given four
repetitions of 12 performance tasks, and one rotating
chair motion sickness test. The order in which the drug or
placebo was assigned to subjects was counterbalanced
and a double-blind procedure was used to administer the
injections. The promethazine used in this study was
manufactured by Wyeth-Ayerst Laboratories. The dura-
tion of action of injectable promethazine is generally
between 4 and 6 hr.
Table 1 shows the test schedule used during the training
and treatment days of this study. On the first day, the
training condition, subjects were given four repetitions of
CTT and SMD tasks, five repetitions of the APTS task,
and a motion sickness test. Each task was repeated once
more following the motion sickness test. Blood and saliva
samples were collected before drug or placebo injections
and at 15 min, 30 min, 1 hr, 2 hr, and 4 hr post-injection.
Samples were also collected following motion sickness
tests. On treatment days, following a baseline of each
performance task, subjects were given an i.m. injection of
promethazine (25 mg or 50 mg) or a placebo injection.
Each performance task was repeated twice before the
motion sickness test and once following the test.
Table 1. Subject test schedule for training and treatment days
time training day 1 treatment days 2, 3, 4
7:45
8:00
8:15
8:30
8:45
9:00
9:15
9:30
9:45
10:00
10:15
10:45
11:00
11:45
12:00
12:15
12:30
12:45
1:15
2:00
2:45
3:00
3:15
baseline blood and saliva
APTS
cTr
SMD
no injection
15 rain blood and saliva
30 min blood and saliva
APTS
1 hr blood and saliva
SMD and CTT
APTS
2 hr blood and saliva
lunch
APTS
SMD and CTT
APTS
CTT and SMD
4 hr blood and saliva
motion sickness test
post-test blood and saliva
APTS
CTT
SMD
baseline blood and saliva
APTS
CTT
SMD
injection
15 min blood and saliva
30 min blood and saliva
APTS
1 hr blood and saliva
SMD and CTT
2 hr blood and saliva
lunch
APTS
CTT and SMD
4 hr blood and saliva
motion sickness test
post-test blood and saliva
APTS
CTT
SMD
Motion Sickness Test
The initial symptoms of motion sickness were induced in
subjects using clockwise rotating chair tests (i.e., cross-
coupled angular acceleration). Tests were conducted in a
Stille-Werner rotating chair located in a sound attenuated
room which was temperature controlled (70 _+2 ° F).
Padded head rests were mounted on the left, right, front
and back of the chair allowing subjects to make head
movements at 45 degree angles from an upright position.
Subjects were blindfolded and were seated in the rotating
chair with the center of rotation through their own vertical
axis (spine). The rotating chair tests were conducted by
initiating rotation at 6 rpm (0.628 rad/s) and incrementing
by 2 rpm (0.209 rad/s) every five minutes, with a maxi-
mum velocity of 30 rpm (3.142 rad/s). During each five
minute period of rotation, subjects were instructed to
make head movements (front, back, left, and right) in
random order at two second intervals. A tape-recorded
voice presented through an overhead speaker provided
instruction for direction of head movements. At the end
of five minutes, rotation continued but the subject was
instructed to stop making head movements and to hold his
head in the upright position. During the next 30 seconds
the subject was asked to describe his symptoms to the
experimenter. The Graybiel diagnostic scale was used to
evaluate the symptom levels (ref. 29). Tests were termi-
nated and rotation stopped when any of the following
occurred: (a) the subject requested termination, (b) the
subject reached malaise level III (8 or more diagnostic
points), or (c) the experimenter felt, from observation of
the subject, that the test should be terminated.
Blood and saliva samples were collected to measure
circulating levels of promethazine, (individual dose
response curves), and comparisons of these levels relative
to changes in performance and mood states were made.
Saliva samples were taken by having the subject chew on
a small piece of parafilm to induce salivation, and then
expectorate into a glass collection vial. Blood samples
were obtained through an indwelling catheter (20 g,
3.2 cm) inserted into a vein on the dorsal surface of the
left hand (and/or through venipuncture of the anticubital
vein of the left arm), into heparinized containers. The
total amount of blood drawn in this study did not exceed
80 cc (2.7 ounces). Samples were then separated and
frozen by the Central Clinical Laboratory at NASA Ames
Research Center. The dru_dose levels of each sample
were calculated in ng/ml, and were obtained by gas
chromatographic analysis performed by an outside
contractor, National Medical Services, Inc.
Automated Performance Test System (APTS)- Most of
the performance testing was conducted using the APTS
(Essex Corp., Orlando FL), a standardized task battery
that required 15 to 18 min to complete. The APTS
software was implemented on a NEC 8201 micro-
computer. This system was selected for portability,
reliability, test automation capability, and utility for short-
duration testing (ref. 30). The present study used ten
performance tests (ref. 8) from the 30 recommended tests
in earlier research (ref. 30). Below is a description of the
10 APTS subtests used in this experiment.
REACT4: Four-choice reaction time (60 seconds or
15 trials). The this test involved the presentation of
a visual stimulus and measurement of a response
latency (in msec) to the stimulus. The subject's task
was to respond as quickly as possible with a key
press to a simple visual stimulus. On this test, four
"outlined" boxes were displayed and one of the four
boxes was "filled." A short tone preceded the filling a
of box to signal that a "change" in the status of a box
was about to occur. The box changed from "outlined"
to "filled." The subject observed the boxes for the
change and then pressed the numeric key
corresponding to the box that changed.
CODSUB: Code substitution (75 seconds). This task was
a mixed associative memory and perceptual speed
task. The computer displayed nine characters across
the top of the screen. Beneath them, the numbers one
through nine were displayed within parentheses. The
subject's task was to associate the number with the
character above it. This was called the subject's
"code." Under the code were two rows of characters
with empty parentheses beneath them. The subject
responded by pressing the number associated with
the character from the code above. When the subject
has completed a row, the bottom row moved to the
top and a new row appeared below. This is a
cognitive and perceptual test with visual search
encoding/decoding and incorporates memory recall
and perceptual speed.
PATRNC: Pattern comparison (75 seconds). This test
measured spatial ability. The task involved compar-
ing two patterns of asterisks that were displayed on
the screen simultaneously. The subject's task was to
determine if the patterns were the same or different
and responded by pressing "S" or "D" key.
STERNB: Sternberg short term memory (75 seconds).
This test involved the presentation of a target set of
four random numbers for one second (positive set),
followed by a series of single numbers presented for
two seconds (probe numbers). The subject's task was
to determine if any of the probe letters were con-
tained in the positive set. The subject responded by
pressing "T" (true) or "F" (false) on the keyboard.
Thisisacognitiveitemrecognitiontaskwhich
reflectshortermscanningrate.
ACM:Aircombatmaneuvering(2minutes).Thiswasa
two-dimensionalpursuittrackingtaskinwhichan
animated"spacecraft"movedslowlyfromleftto
rightacrossthetopofthescreen.Thesubject'stask
wastolaunchmissilesbypressingthespacebar,and
"hit"thespacecraft.Thepositionofthe"missile
launchers"wascontrolledbytheleftandrightarrow
keys.Thesubjectwasscoredonthenumberof"hits"
madewithintheallottedtime.
PHTAP:Preferredhandtapping(10seconds,2trials
each).Thetappingtestsmeasuredmanualmotorskill
andcoordination.Thesubjectwasrequiredtopress
theindicatedkeysasfastaspossiblewiththefingers
fromthepreferredhand(PHTAP),thenonpreferred
hand(NPTAP),oronefingerfromeachand
(TFTAP).Correctresponsesarebasedonthenumber
ofalternatekeypressesmadein theallottedtime.
NPTAP:Non-preferredhandtapping(10seconds,2trials
each).
TFTAP:Twofingertapping(10seconds,2trialseach).
REASON:Grammaticalreasoning(90seconds).This test
was designed to measure logical reasoning ability.
Stimulus items were sentences of varying syntactic
structure (e.g., A precedes B) accompanied by a set
of letters (e.g., AB). The sentences were generated
from possible combinations of five conditions:
(1) active versus passive wording, (2) positive versus
negative wording, (3) key words such as "follows"
and "precedes," (4) order of appearance of the two
symbols within the sentence, and (5) order of the
letters in the simultaneously presented symbol set.
The subject's task was to determine (i.e., read and
comprehend) whether the sentence correctly
described the sequence of the symbols in the
symbolic set which appears to the right of the
sentence. The subject responded by pressing the
"T" (true) or "F" (false) keys.
MANKIN: Mankin spatial transformation (60 seconds).
This test measured the ability to spatially transform
mental images and determine the orientation of a
given stimulus. A figure of a sailor is presented on
the screen with a box below his feet and a box in
each hand. A pattern (XXX or 000) appeared in the
box below which matched the pattern in the box in
one of his hands. The figure stands either facing
away or toward the subject. The objective of this task
was to determine which hand (right or left) matched
the objects that appeared in the box on which the
sailor is standing. The subject responded by pressing
one of the two arrow keys, (i.e., to indicate left or
right hand).
Mood Test-A visual analog scale mood test (refs. 14
and 31 ) was incorporated into the APTS performance
software. The mood test initiated the APTS test battery to
avoid possible modulation of mood responses by the
performance tests. This test provided 21 levels of mood
state resolution on a 10-cm scale which was displayed on
a computer monitor. For example, when reporting his
perceived state of arousal, the subject moved the cursor
(with arrow keys) along the scale which ranged between
SLEEPY (score = 0) to ALERT (score = 10).
The mood scales were allocated four each into two
composite dimensions (ref. 27). The global "Affective
Mood Dimension" included four measures of feelings or
affective states and incorporated physical discomfort
(very high (0) to very low (10)), elation, (sad (0) to happy
(10)), psychological tension (tense (0) to relaxed (10)),
and contentedness (unpleasant (0) to pleasant (10)). The
global vigor or "Activation Mood Dimension" incor-
porated four measures of activation including fatigue
level (weary (0) to energetic (10)), arousal state (sleepy
(0) to alert (10)), motivation to perform (bored (0) to
interested (10)), and ease of concentration (very low (0)
to very high (10)). The physical discomfort scale indi-
cated the state of physical uneasiness or the extent of mild
aches and pains (very high (0) to very low (10)).
The Sleep Quality Scale-- This scale rated whether or not
subjects had experienced trouble falling asleep. Scores
were rated on a scale of "much worse" (score = 0) to
"much better" (score = 10). This scale also required the
subject to report the number of previous night waking
episodes, which was scored on a total episode (score = 0
to 6) scale. The subjects rated their overall performance
relative to the previous test battery from "much worse"
(score = 0) to "mucfi better" (score = 10).
Critical Tracking Task (CTT)- The CTT is available
commercially as the FACTOR 1000TM (manufactured by
Performance Factors, Inc., Alameda, CA). This pursuit
tracking task was performed by a subject seated at a desk
with a PC computer. To the side of the keyboard was a
small knob which could be operated with one hand. On
the computer screen, a horizontal line was displayed with
a perpendicular "cross-hair" line at the center. As a trial
began, the perpendicular line (or "target") gradually
moved off center (to the left or right). The subject' s task
was to keep this target as close to center as he could by
turning the knob. As the trial continued, this became
increasingly difficult because the target moved faster and
faster, until maintaining control became impossible, and
the target moved completely off the screen, marking the
end of a trial. Hence, this task required the operator to
activelystabilize,bycontinuouslycorrectingdisplayed
errors,anotherwisedivergentlyunstablecontrolelement.
The performance measure was the "critical instability"
level (i.e., the rate of divergence of the pointer) at the
point when control was lost. The score for each trial was
displayed at the bottom of the screen. Typically, a trial
lasted I0 to 15 sec, with 30 sec being an extremely long
trial. During a CTT session, subjects performed twenty-
five trials in five blocks of five trials with a short rest
between blocks. The first set of five trials was considered
practice and were not included in the analysis.
Symptom Monitoring Device (SMD)- The SMD,
developed at NASA, contained a battery operated 8051-
derivative CMOS microcomputer with 32-Kbyte memory
and a seven-key computer keypad (three for the thumb
and four for each of the remaining fingers of the right
hand) (ref. 32). Data were independently stored on the
microcomputer itself (autonomous mode), or were
captured and transmitted to another PC computer via a
built-in serial port (tethered mode). When in tethered
mode, text was typed into the keypad while a program
read the data. Specific combinations of key-presses were
displayed as alphanumeric characters on the PC's
monitor. Within the SMD, the microprocessor was
enclosed in a durable polycarbonate case with separate
mounting for the key-pad, and this device was attached to
the right arm rest of the rotating chair. Table 2 shows the
combination of key strokes each subject was expected to
learn. Figure 1 shows a top-down view of the 7-key SMD
keypad as operated by the subject's right hand.
On the first day of the study (training day), subjects were
given five sessions prior to the rotating chair test. During
each session, subjects were verbally instructed to enter
specific symptoms using the keypad, in random order.
During the first session, subjects learned the key presses
that represented eight alphabetic characters (A, E, D, S,
N, T, H, and Z). During the second session, emphasis
was placed on teaching subjects which combination of
alphabetic characters represented specific motion sickness
symptoms. Each subject was read 100 symptoms (nine
different symptoms in random order). Throughout both
the first and second sessions, subjects viewed a computer
screen which displayed each entry, thereby providing
feedback on correct or incorrect typing. During the third,
fourth and fifth sessions, subjects were not allowed to
view the computer screen and an experimenter recorded
subjects' responses. Each subject had reached a training
plateau by the fifth session on training day one. The
criterion for learning was no more than 15 errors out of
100 symptoms entered with the key-pad. A sixth training
session followed the rotating chair test. On the subsequent
days of the study, each subject participated in four SMD
sessions, where again, their task was to enter 100 key-
stroke combinations in response to a random ordered list
of symptoms read by the experimenter.
Table 2. Symptom key-stroke list
Symptom Letter Key*
temperature
dizziness
headache
drowsiness
sweating
salivation
nausea
epigastric awareness
epigastric discomfort
t
d
h
Z
S
sa
n
ea
ed
2+4
la+2+3
1+5
la+3+5
4
4,2+3
3+4
2,2+3
2, Ia+2+3
Symptom level Number
mild 1 lc
moderate 2 lc + 2
severe 3 Ic + 3
* The + indicates that these keys were pressed simultaneously.
3
4
2DD5
E] D
Figure 1. Top-down view of the 7-key SMD key-pad. The subject used his right hand to enter the different combinations of
key strokes representing specific motion sickness symptoms (refer to table 2). The keys were numbered as follows: l a,
l b, and lc entered with thumb, 2 entered with index finger, 3 entered with middle finger, 4 entered with ring finger, and 5
entered with the little finger.
Statistical Analysis
Statistical analyses of the results were performed by
ANOVA and MANOVA to examine performance
changes across treatment conditions and sessions
(repeated trials). The Greenhouse-Geisser formula
(ref. 33) was used to adjust the P-values for those tests
involving repeated measures.
The APTS performance tests which were scored on
accuracy (number correct responses minus the number
of errors), and mid-mean latency in msec included:
CODSUB, PATRNC, STERNB, REASON and
MANKIN. The test of reaction time (REACT4) was
scored only on mid-mean latency. Tests of manual
dexterity (PHTAP, NPTAP, TFTAP) were scored by
counting the number of alternate presses. The tracking
task ACM was scored on number of hits subjects made
on the targets.
A MANOVA was performed to determine differences in
APTS subtest scores as related to drug condition (25 mg,
50 mg, and placebo), and sessions. There were three
sessions: a baseline prior to injections, l-hr and 4-hr post-
injection. Comparisons of drug conditions across sessions
controlled for the possible effects of diurnal variations on
performance which are magnified by antihistaminic drugs
(ref. 34) and practice effects between successive tests.
Task data were obtained within 30 rain of the baseline,
1 hr, and 4 hr blood and saliva samples. Data collected
on the first day were not included in the analyses because
this day was used to train subjects on each task and to
establish a performance plateau (task proficiency and
stability). The number of sessions required for APTS
performance test means and variances to stabilize was
determined by Bittner's methods (ref. 35).
The performance metric used for the CTF tracking task
is referred to as a critical instability level (ref. 19).
The SMD task was scored by the number of incorrect
responses out of 100 key-pad entries of symptoms.
Separate ANOVAs were performed for CTr and SMD
scores (3 experimental conditions by 3 sessions).
Drug dosage-associated performance decrements were
evaluated for potential operational significance by
establishing blood alcohol level dose equivalency (BAL).
A study of APTS subtest performance changes associated
with different fixed BAL (0.0, 0.05, 0.10, 0.15%) pro-
vided conversion tables (ref. 20). This study employed a
subject group (21-42 year old males) comparable to the
subject _oup in the present study. Test scores from the
BAL study were converted from the number of correct
responses to net accuracy scores for the appropriate
subtests. Linear regression of performance decrement
against BAL% was done. The BAL dose equivalency was
considered valid for a subtest where R 2 > 0.81 (P < 0.05,
1-tail test).
Mood test and sleep quality data were ordinal and
therefore separately analyzed by nonparametric methods,
Friedman's ANOVA with Wilcoxon's paired compari-
sons for repeated measures.
Motionsicknesstolerancewasmeasuredasthe
accumulatednumberof rotationstoleratedbyeach
subjectduringrotatingchairmotionsicknesstests.
AnANOVAwasperformedtoexaminedifferencesin
motionsicknesstoleranceacrossthetrainingcondition
andthreetreatmentconditions(25mgofpromethazine,
50mgofpromethazine,andplacebo).
Inasupplementarynalysis,dataofthepresentstudy
werecomparedtoarchivedataonmotionsickness
toleranceofsubjectsgivenAutogenicFeedbackTraining
(AFT)(refs.36and37),aphysiologicaltrainingmethod,
andano-treatmentcontrolgroup.Fromthisarchive,it
waspossibleto"select"12menwhohadbeengiven
AFTEaspartofearlierstudiesand12menwhohad
participatedascontrols(notreatment).Thesesubjects
werematchedtothepromethazinestudysubjectsforage,
sex,andsusceptibilitytomotionsicknessbasedonthe
durationof theirfirstrotatingchairtest.Therotatingchair
motionsicknesstestsgiventoallsubjectswereidentical
andhadthesameintervalbetweentests(oneweek).
Results
Table 3 shows the latin-square design used to counter-
balance the order of presentation of drug and placebo
conditions. This latin square design was compromised
when two subjects were excluded from the study, and
when subject 8 was mistakenly given the protocol for
subject 14. Subject 5 reported extreme discomfort from
this medication and subject 7 began taking another
medication, fluoxetine, for reasons unrelated to this study.
Subject 6 participated in all experiment sessions but was
found to be labyrinth-defective (i.e., not susceptible to
motion sickness), and therefore his data are not included
in the analysis on motion sickness tolerance. Since
practice effects in APTS subtests are commonly observed
even after subject training (ref. 14), further analysis of
practice effects in this study was necessary to distinguish
performance test changes in response to the experimental
protocol from those due to practice effects resulting from
an unbalanced order of presentation between successive
experimental trials.
Linear regressions were performed on baseline sessions
of the placebo, 25 mg and 50 mg conditions in order of
presentation for each APTS subtest. There were seven
sessions (repetitions of task batteries) between the first
and last baseline session on the treatment days for each
subject. Although all tests showed improvement between
sessions 1 and session 9, significant practice effects were
found only for the CODSUB (t 34 = 2.39, p < 0.022,
+3. l%/session), MANKIN (t 34 = 2.08, p < 0.045,
+3.0%/session) subtests and for composite performance
Table 3. Order of presentation for treatment conditions
Subject Placebo
1
2
3
4
5*
6*
7*
8
9
10
11
12
13
14
15
25 mg 50 mg
4 2
3 2
3 4
4 3
2
2 3
- 2
3 2
3 4
4 3
2 4
2 3
2 4
2 3
2 3
* Subjects 5 and 7 were excluded from the experiment.
Subject 6 was found to be labyrinth-defective and his
motion sickness data were not included in analyses of
drug effects on motion tolerance.
(z-scores, t 34 = 5.65, p < 0.002). Composite scores are
computed from a mean of subtests which were common
to our performance battery and an earlier study by
Kennedy (ref. 21). This index excluded the ACM and
TFrAP scores. Paired t-tests were then done on these
three tests for the placebo/25 mg, placebo/50 mg and
25 mff50 mg baseline sessions to determine if the
unbalanced order of presentation for each combination
was associated with significant practice effects. Out of
9 combinations (3 tests × 3 paired sessions), only
MANKIN (25 mg vs. 50 mg conditions, +9.7%,
t 11 = -2.27, was suggestive of a protocol practice effect,
which given the Bonferroni correction for 9 paired
sessions (alpha = 0.05/9 = 0.006), was not statistically
significant.
Figure 2 shows the group means (+ S.E.M.) for blood
serum and saliva concentrations of promethazine taken
throughout test days.
Baseline blood and saliva samples were taken before
injections were administered. Concentration of the drug in
each subsequent sample and the time from injection when
the sample was taken are shown. Note that less data is
available on serum levels because of procedural diffi-
culties in obtaining the blood. The last samples were
taken immediately following rotating chair tests, which
occurred between 5 hr and 6 hr following injections
50 7-
40
_ 30
_ 2o
lO
Serum Levels
D25mg (N=10)
[] 50mg (N=9)
Saliva Levels
5o--
!
"E 30
10 _
15 30 1 hr 2 hr 4 hr post
min min chair
test
EI2$mg (N=12)
13 50mg (N=13)
Figure 2. Promethazine concentration in serum and safiva. The data represent the mean (_+S.E.M.) serum and safiva
concentrations of promethazine (25 mg and 50 mg dosages). The x-axis labels represent post-injection times.
(dependent upon the duration of time that subjects could
tolerate the motion sickness tests). Group means for
serum levels show promethazine peaking at 1 hr post
injection for the 50 mg dose, with the peak time at 30 min
for the 25 mg dose. As expected, during all sample
periods the levels were higher for the 50 mg than the
25 mg dose. Group means for saliva concentrations show
that the 50 mg dose peaks at 4 hr, rather than ! hr. As
measured in saliva, circulating levels increased more
slowly than in blood serum which is already high by
15 min and remains fairly stable over a 5-6 hr period.
Linear regressions were performed on circulating levels
of promethazine (25 mg and 50 mg doses) in both serum
and saliva samples obtained at 1 hr, 2 hr, 4 hr, and
following rotating chair motion sickness tests (approxi-
mately 6 hr) against blood alcohol level equivalency
scores from the corresponding time periods. Significant
positive correlations between serum levels and BAL
scores were found for the 25 mg dose during the period
following the rotating chair test, (n = 8, r = 0.88,
p < 0.004), while the 50 mg dose was significant at 4 hr
post-injection (n = 11, r = 0.65. p < 0.03). Separate linear
regressions for saliva concentration levels vs. BAL scores
showed significant correlations at 1 hour post-injection
for both the 25 mg dose (n = 10, r = 0.77, p < 0.009) and
50 mg dose (n = 11, r = 0.65, p < 0.03).
Dose Effects on Performance Tests
Performance test means and variances stabilized by a
mean of 2.5 sessions out of a total of 6 training sessions
presented during the training day. The MANOVA results
of APTS scores revealed a significant overall interaction
of treatment conditions by sessions, F (80,116) = 1.5,
p < 0.02. Table 4 shows the specific subtests and their
P values. Table 5 shows the probabilities of no difference
for planned comparisons (separate one-way A.NOVAs)
which were performed to determine dru_placebo effects
on performance at 1 hr and 4 hr. Figures 3 and 4 show the
average scores of each subtest across sessions (baseline,
1-hr, 4-hr, and post-chair test).
Table 4. Results of APTS subtests
Test Accuracy
REACT1
CODSUB
PATRNC
STERNB
ACM
PHTAP a
NPTAP a
TFTAP a
REASON
MANKIN
ns
ns
:,y.
ns
Latency
** ns
ns *
a Scored on number of alternate presses.
* P < .05, ** P < .01, *** P < .001
Table 5. Secondary comparisons of APTS subtest scores
Accuracy
Placebo/25 mg Placebo/50 mg
REACT1
CODSUB
PATRNC
STERNB
NPTAP a
TFTAP a
REASON
MANKIN
lhr 4hr
:,g _ :¢
1 hr 4hr
*** nS
ns ***
25 m_50 mg
1 hr 4hr
m
** ns
** ns
** ns
** ns
ns
ns
ns
ns
ns
ns
Latency
REACT1
CODSUB
PATRNC
STERNB
NPTAP a
TFTAP a
REASON
MANKIN
Placebo/25 mg
lhr 4hr
ns **
* ns
ns ns
Placebo/50 mg,
1 hr 4hr
25 mg/50 mg
1 hr 4hr
m m
ns ns
*** ns
** ns
ns ns
ns ns
ns ns
ns ns
ns ns
a Scored on number of alternate presses.
* P < .05, ** P < .01, *** P < .001
10
40 Code Substitution 3900 • Grammatical Reasoning
•>, 35 3600 " IR
30 = ,30o
o° i
25 3000
20 2700
1500 ] Short Term Memory 530
/
1300] El o 480
11 O0 430
900 ..... 380
Reaction Time
Pattern Recognition
1300 - 60
1200 _ 55
11oo g
1000 ,_ 50
900 45
fit,Ill
Baseline 1-HR 4-HR Post Chair Baseline 1-HR 4-HR Post Chair
test test
Figure 3. APTS subtest scores across treatment conditions. The data represent the mean (n = 13) accuracy (number of
correct responses minus number of errors) and or latency (msec) scores on code substitution, grammatical reasoning,
pattern recognition, and spatial transformation tasks on the placebo day and on days when promethazine was given. The
x-axis shows the times relative to injection when tasks were given. The baseline task preceded the injections.
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Figure 4. APTS, SMD and C7-/- task scores across treatment conditions. The data represent the mean (n = 12) latency
(msec) on short-term memory and reaction time tasks, total number of finger taps (left hand and both hands) on the
manual dexterity task, number of errors (incorrect key presses) on the symptom monitoring device, and score (rate of
divergence of the pointer) on the critical tracking task. The x-axis shows the times relative to injection when tasks were
given. The baseline task preceded the injections.
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Dose Effects on Critical Tracking
Results on CTT scores showed a highly significant
conditions by sessions interaction, F(2.78,33.39) = 18.14,
p < 0.00001. Planned comparisons, one-way ANOVAs,
were performed to determine drug/placebo effects on this
tracking task at 1-hr and 4-hr post-injection. At 1 hr, the
25 mg and 50 mg conditions showed significantly lower
scores (less time on target) when compared to the placebo
condition, F(1,12) = 32.1, p < 0.0001 and F(I,12) =
31.36, p < 0.0001, respectively. At 4 hr, again both drug
conditions showed significantly lower scores than the
placebo, F(I,12) = 17.40, 12< 0.0013; and F(1,12) =
40.28, 12< 0.00001, respectively. Further, a comparison
between the 50 mg and 25 mg conditions at 4 hr showed
that tracking scores were significantly lower for 25 rag,
F(1,12) = 11.28, 12< 0.0049. Figure 4 shows the average
CTT scores obtained during each condition.
Dose Effects on Symptom Monitoring
The analysis of SMD scores revealed a significant
condition by session interaction, F(2.1,25.2) = 3.25,
p < 0.05. Planned comparisons, one-way ANOVAs, were
performed to examine drug/placebo effects on this task at
1 hr and 4 hr. At 1 hr, both the 25 mg and 50 mg condi-
tions when compared to the placebo condition showed
significantly higher scores (more errors), F(1,12) = 8.82,
p < 0.012 and F(1,12) = 8.53, p < 0.013, respectively. At
4 hr, again both drug conditions resulted in significantly
more errors than the placebo condition, F(1,12) = 11.89,
p < 0.005 and F(1,12) = 10.01, p < 0.008. Comparisons
between the 25 mg and 50 mg conditions revealed no
significant differences at either 1-hr or 4-hr post-injection.
Figure 4 shows the average SMD scores across sessions
for each condition.
Dose Effects on Sleep and Psychological Tension
Analyses on the two sleep scales by four conditions
(training, placebo, 25 ms, and 50 ms) revealed no sleep
quality changes for trouble falling asleep (SLEEP,
X 2 (3) = 4.3, NS), or number of awakenings, (WAKE,
X 2 (3) = 1.5, NS). Psychological tension showed no
change across sessions (TENSE, X 2 (11) = 7.9, NS).
These findings indicate that performance or mood
changes observed in response to drug treatments were
not attributable to changes in previous night's sleep
quality, psychological tension or anxiety.
Dose Effects on Mood
Significant drug effects on the Activation Mood
Dimension and its constituent scales were found, with
maximum deterioration evident in the arousal state
and fatigue level scales. These scales showed marked
deterioration at 1-hr post-injection with 50 mg relative
to the 25 mg dose. Changes in Activation Mood
Dimension scales were significant across drug condi-
tions, (X 2 (3) = 8.4, p < 0.03), and across sessions
(X2 (11) = 35.7, p < 0.0005). Only the arousal state
scale had statistically significant changes between
25 mg and 50 mg doses.
The Affective Mood Dimension scales were relatively
unaffected except for a progressive increase in physical
discomfort following the 50 mg dosage (X 2 (11) = 22.7,
p < 0.02).
Performance Impairment Index
Subject impairment was defined as six or more perfor-
mance subtests out of ten total tests where performance
decrements relative to control exceeded 5% (based on
Turnage et al., ref. 38). The index number was the
number of subjects meeting impairment criterion. There
was a difference between the 25 mg dose (which induced
impairment in 4 of the 12 subjects) and the 50 mg dose,
(which induced impairment in 7 of the 12 subjects). These
results indicate that although few significant changes in
performance were found between the 25 mg and 50 mg
dosages, the number of impaired subjects nearly doubled,
thereby indicating that the higher dose may have
undesirable operational implications for performance
proficiency.
Dose Effects and BAL%
Individual subject BAL scores at 1 hr and 4 hr following
injections of 25 mg and 50 mg of promethazine are shown
in table 6. At 1-hr post-injections the BAL scores were
highly variable, ranging from 0.000 to 0.243% for 25 mg
and from 0.000 to 0.429% for 50 mg. BAL scores
calculated 4 hr after injections ranged from 0.022 to
0.196 for 25 mg and from 0.017 to 0.418% for 50 mg.
The subject group means exceeded the California state
legal limit for BAL (0.080%) on all conditions reported.
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Table 6. Individual blood alcohol equivalency
percentages following promethazine injections
Subject
1
2
3
6
8
9
10
11
12
13
14
15
25 mg
1 hr 4 hr
0.015 0.022
0.004 0.027
0.243 0.270
0.086 0.088
0.014 0.029
0.000 0.196
0.129 0.122
0.032 0.062
0.107 0.045
0.133 0.129
0.125 0.111
0.050 0.121
50 mlg
1 hr 4 hr
0.076 0.034
0.063 0.078
0.429 0.418
0.093 0.081
0.288 0.281
0.000 0.133
0.086 0.080
0.091 0.040
0.128 0.031
0.212 0.174
0.110 0.082
0.044 0.017
Mean = 0.085 0.105 0.137 0.128
Dose Effects on Motion Sickness
Figure 5 shows the _oup means for motion sickness
tolerance across the four experimental conditions. The
analysis of motion sickness data showed a significant
effect for conditions (F(3,33) = 6.70, p < 0.01. Planned
comparisons, one way ANOVAs, revealed no significant
differences in motion sickness tolerance between training
and placebo conditions and between the 25 mg and 50 mg
conditions. However, motion sickness tolerance was
significantly higher for the 25 mg dose than the placebo,
F(I,11) = 14.44, 12< 0.003; and was higher for the 50 mg
dose than for placebo, F(1,11) = 6.19, 12< 0.03.
Figure 6 shows the individual subjects' motion sickness
tolerance across test conditions. Half of the subjects
showed greater motion sickness tolerance with the 25 mg
dose when compared to the 50 mg dose of promethazine.
AFT vs. Drug vs. Control Effects on Motion Sickness
Tolerance
A two-way ANOVA was performed to examine
differences between three groups (AFT, Control and
Promethazine) over four motion sickness tests. Figure 7
shows the average number of rotations for each group
during four rotating chair tests. The main effects for
groups and tests were significant (F(2,132) = 20.02,
p < 0.0001 and F(3,132) = 10.33, p < 0.0001, respec-
tively), and the group by test interaction was also
significant (F(6,132) = 4.19, p < 0.0007).
Comparisons of the baseline tests of the three groups
(Bonferroni t-tests) showed no significant differences in
motion sickness tolerance, indicating that the groups were
matched for initial susceptibility. When 2 hr of AFTE
was compared to 25 mg and 50 mg of promethazine, no
significant differences were found. However, comparison
of 4 hr of AFTE revealed that motion sickness tolerance
was significantly higher than for subjects given 25 mg
(t = 1.33, df = 132, p < 0.005) and 50 mg of promethazine
(t = 1.36, df = 132, p < 0.005). Finally, 6 hr of AFTE
was significantly higher than 25 mg (t = 5.54, df = 132,
p < 0.001) as well as 50 mg (t = 5.57, df= 132,
p < 0.001). Changes in motion sickness tolerance of
individuals of each group are shown in figure 8. Four
of the 12 subjects receiving AFTE had completely
suppressed motion sickness symptoms after 6 hr of
training. Of the subjects given promethazine, however,
only one showed a large improvement in tolerance for
both doses, while half of the subjects showed better
tolerance after 25 mg than for 50 mg.
Discussion
Both dosages of promethazine were associated with
significant decrements in performance on 8 of the
10 APTS subtests, as well as the CTT and SMD tasks.
These findings are consistent with Wood (ref. 5) and
Parrot and Wesnes (ref. 4), who observed performance
decrements following oral ingestion of this medication.
The studies using i.m. injections of 25 mg and 50 mg
reported only on changes in motion sickness during
parabolic flight (refs. 2 and 3), or space sickness (ref. 39)
tolerance without measuring effects on performance.
The two tests which did not change significantly were
PHTAP (preferred hand tapping), a test of manual
dexterity, and the ACM (air combat maneuver) which
measures eye-hand coordination. It is possible that a well
learned manual dexterity task using the dominant hand is
less likely to deteriorate in response to this medication. It
is important to note, however, that the other two tests of
manual dexterity (NPHTAP, non-preferred hand tapping
and TFTAP, two-finger tapping) were significantly
degraded by promethazine. The lack of a significant
decrement in performance of ACM may be related to
observations by Kennedy (ref. 8) that learning of this task
was slow to stabilize and that it was not an optimal test
of eye-hand coordination. This conclusion is further
supported by our findings that the C'VI', which has been
widely used to test this performance dimension (refs. 38
and 40-43), showed significant decrements.
The SMD was developed for this study and has not been
previously validated as a research performance task in
contrast to the APTS and the CTT. However, analyses
showed that this task also was impaired by injections of
promethazine and that the changes associated with the
time course of medication and the dose (25 mg vs. 50 mg)
was in fact very similar to the findings for the APTS and
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Figure 5. Motion sickness tolerance across treatment conditions. The data represent the mean (+_S.E.M.) number of
rotations tolerated on the training day (no injections), and on days when the placebo and promethazine (25 mg and 50 mg
dosages) injections were given. Subjects could achieve a maximum of 1170 rotations (65 min of continuous rotation)
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Figure 6. Motion sickness tolerance of individual subjects on the training day and on days when the placebo and
promethazine injections were given. Subjects could achieve a maximum of 1170 rotations (65 min of continuous rotation)
during motion sickness tests.
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CTT. As the SMD was designed to "simulate" a payload
activity which might be performed by crewmembers
aboard shuttle, these results further serve to emphasize
the impact of this antimotion sickness medication on
imbedded task components of operational performance.
Significant performance decrements measured at 1-hr and
4-hr post-injection were associated with high serum levels
of promethazine for both dosages. Although mean per-
formance decrements were greater for 50 mg than for
25 mg, there were no significant differences between
dosages on most of the tests measured at 1 hr and 4 hr.
Although performance measures were obtained no earlier
than 1 hr, it is possible that decrements may also be seen
as early as 15 min post-injection. Concentration levels
in saliva and corresponding decrements in performance
are not as clear, as the circulating levels increase more
gradually throughout the day. Therefore, dose response
measures in saliva may be less accurate than serum for
assessing performance changes over time.
Another objective of this study was to examine the
possibility of any negative effects of this medication on
individual subjective experience of malaise or "well
being." To answer this question, subjective report scales
on mood and sleep were added to this study. It was clear
from these tests that decline in performance on days when
promethazine was administered was not related to sleep
disturbances (a significant potential intervening source of
variance). The MOOD scale results showed significant
changes in individual subjective experiences in response
to medication, with the 50 mg dose having the greatest
negative impact.
As a further measure of the effect of promethazine on
subjective state, we calculated blood alcohol equivalency
scores (BAL) for each subject. The establishment of
alcohol dose equivalency levels for performance
decrements provides a useful metric for evaluating the
potential operational significance of drug treatment
effects on performance because: (1) alcohol is known to
be a global depressant with well documented impacts on
performance and operational readiness; and (2) consid-
erable research has been reported on the calibration of
safe and unsafe alcohol dosages (ref. 20). These blood
alcohol levels clearly exceed the legal limits for alcohol
influenced driving impairment (0.08-0.10%) and are
much larger than the 0.025% BAL which is sufficient to
induce serious errors in pilots during B727 and B232
simulator performance tests (ref. 44). Therefore, the
promethazine dosages used in this study induced blood
alcohol equivalent levels of performance decrement
which clearly exceed legal and operational thresholds for
performance impairment (BAL = 0.085% for 25 mg
injections and 0.137% for 50 mg).
These results indicate that a very wide range of individual
responses to promethazine in terms of BAL dose equiva-
lent performance decrements, with some individuals
being severely impaired with respect to operational
performance. Both the impairment index and the BAL
dose equivalent data indicate that a higher proportion of
individuals are performance impaired at the 50 mg dose
than at the 25 mg dose.
Lastly, the results of this study showed that motion
sickness tolerance was significantly increased with both
dosages of promethazine when they were compared to the
placebo or a no treatment baseline condition (training
day). However, there was no statistical difference in
motion sickness tolerance between 25 mg and 50 mg
doses of promethazine. In fact, half of the subjects
showed greater motion sickness tolerance with the 25 mg
dose. And, only one subject clearly demonstrated an
improvement in tolerance with both dosages of
promethazine.
These data indicate that effective doses of promethazine
used as a prophylactic treatment for motion sickness and
space motion sickness may significantly impair most
individuals with respect to their operational performance.
Current policy involves giving a single 50 mg i.m. injec-
tion to sick crewmembers regardless of weight, gender, or
symptom severity. Data from the present study strongly
indicate that fixed doses of this medication are inappro-
priate and that even individually adjusted dosages may
not lessen its degrading effects on performance. As
mentioned, both doses increased motion sickness toler-
ance when compared to a placebo but this study does not
demonstrate how this medication compares to other
treatments or to habituation (i.e., repeated exposure to
motion sickness tests, no treatment).
The analysis comparing data of the present study to
archived data (AFT and a no-treatment control) revealed
that neither 25 mg or 50 mg doses of promethazine
resulted in increases in tolerance greater than the control
group, and the AFT treatment provided significantly
greater protection from symptoms. The question remains,
is the relatively small degree of protection from
symptoms achieved through either dose of promethazine
"worth" the pervasive and long lasting decrements in
performance observed? If these side effects are less
pronounced in space as reported (ref. 1), it would be
valuable to use a performance battery similar to the APTS
to assess individual differences in response to this
medication. Research in space should continue to evaluate
this and other possible countermeasures with the goal of
finding that treatment or combination of treatments most
effective for individual crewmembers.
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